Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Prophylaxis of Graft-Versus-Host Disease (GVHD) with Pentostatin, Tacrolimus, and “Mini”-Methotrexate (MTX): A Phase I/II Controlled, Randomized Study in Unrelated Donor (UD) Transplantation.

Blood (2007) 110 (11): 40.

https://doi.org/10.1182/blood.V110.11.40.40

Published: 2007

Journal Articles

Long-Term Follow-Up of IV Busulfan (Bu) with Fludarabine (Flu) vs IV Bu with Cyclophosphamide (Cy) as Pre (Allogeneic) Transplant Conditioning Therapy for AML/MDS.

Marcos De Lima, X. Wang, P.F. Thall, D. Couriel, R.B. Jones, E.J. Shpall, U. Popat, S. Giralt, M. Korbling, R. Champlin, B.S. Andersson

Blood (2006) 108 (11): 322.

https://doi.org/10.1182/blood.V108.11.322.322

Published: 2006

Journal Articles

Influence of Allele Level HLA Typing on Unrelated Donor (UD) Transplantation for High Risk Myeloid Leukemias.

S. Parmar, M. Fernandez-Vina, P. Liu, P. Cano, B. S. Andersson, M. Munsell, S. Giralt, J. McMannis, E. J. Shpall, D. Couriel, S. Ghosh, R. Champlin, M. de Lima

Blood (2005) 106 (11): 2916.

https://doi.org/10.1182/blood.V106.11.2916.2916

Published: 2005

Journal Articles

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine and Melphalan (FM) Reduced Intensity Conditioning (RIC) for High-Risk AML/MDS.

B. Oran, R. Saliba, S. Giralt, D. Couriel, A. Carrasco-Yalan, C. Hosing, M. Shahjahan, E. de Meis, A. Anagnostopoulos, P. Anderlini, S. Ghosh, I. Khouri, R. Champlin, M. de Lima

Blood (2005) 106 (11): 838.

https://doi.org/10.1182/blood.V106.11.838.838

Published: 2005

Journal Articles

Results of a Phase I/II Study of Gemtuzumab Ozogamicin Added to Fludarabine (F), Melphalan (M) and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed Myeloid Leukemias.

Marcos de Lima, S. Giralt, Z. Caldera, G. McCormick, M. Qazilbash, P. Anderlini, E. J. Shpall, C. Hosing, M. Donato, S. Kornblau, I. Khouri, T. Martin, D. Couriel, R. Champlin

Blood (2005) 106 (11): 841.

https://doi.org/10.1182/blood.V106.11.841.841

Published: 2005

Journal Articles

Phase I/II Study of Gemtuzumab Ozogamicin (GO), Fludarabine and Melphalan (FM) Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in AML/MDS.

M. de Lima, P. Thall, M. Shahjahan, W. Xuemei, D. Couriel, P. Anderlini, C. Hosing, M. Qazilbash, G. McCormick, C. Ippoliti, M. Donato, T. Martin, L. Metoyer, L. Griffin, P. Kebriaei, R. Champlin, S. Giralt

Blood (2004) 104 (11): 1824.

https://doi.org/10.1182/blood.V104.11.1824.1824

Published: 2004

Journal Articles

Pentostatin, Tacrolimus, and “Mini”-Methotrexate for Graft-Versus-Host Disease (GVHD) Prophylaxis: A Phase I/II Controlled, Randomized Study.

M. de Lima, D. Couriel, M. Munsell, M. Westmoreland, H. Shah, J. deJesus, C. Hosing, S. Ghosh, P. Anderlini, J. Gajewski, B. Andersson, S. Kornblau, B. Hocking, C. Ippoliti, S. Giralt, E. Shpall, R. Champlin

Blood (2004) 104 (11): 727.

https://doi.org/10.1182/blood.V104.11.727.727

Published: 2004

Journal Articles

Transplantation of Cord Blood Expanded Ex Vivo with Copper Chelator.

E. Shpall, M. de Lima, K. Chan, R. Champlin, A. Gee, P. Thall, K. Komanduri, D. Couriel, B. Andersson, C. Hosing, S. Giralt, S. Safa Karandish, T. Tara Sadeghi, B. Muriera, T. Peled, F. Grynspan, A. Nagler, J. McMannis

Blood (2004) 104 (11): 982.

https://doi.org/10.1182/blood.V104.11.982.982

Published: 2004

Journal Articles

CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies

D Mavroudis, E Read, M Cottler-Fox, D Couriel, J Molldrem, C Carter, M Yu, C Dunbar, J Barrett

Blood (1996) 88 (8): 3223–3229.

https://doi.org/10.1182/blood.V88.8.3223.bloodjournal8883223

Published: 1996

NARROW

Prophylaxis of Graft-Versus-Host Disease (GVHD) with Pentostatin, Tacrolimus, and “Mini”-Methotrexate (MTX): A Phase I/II Controlled, Randomized Study in Unrelated Donor (UD) Transplantation.

Long-Term Follow-Up of IV Busulfan (Bu) with Fludarabine (Flu) vs IV Bu with Cyclophosphamide (Cy) as Pre (Allogeneic) Transplant Conditioning Therapy for AML/MDS.

Influence of Allele Level HLA Typing on Unrelated Donor (UD) Transplantation for High Risk Myeloid Leukemias.

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine and Melphalan (FM) Reduced Intensity Conditioning (RIC) for High-Risk AML/MDS.

Results of a Phase I/II Study of Gemtuzumab Ozogamicin Added to Fludarabine (F), Melphalan (M) and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed Myeloid Leukemias.

Phase I/II Study of Gemtuzumab Ozogamicin (GO), Fludarabine and Melphalan (FM) Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in AML/MDS.

Pentostatin, Tacrolimus, and “Mini”-Methotrexate for Graft-Versus-Host Disease (GVHD) Prophylaxis: A Phase I/II Controlled, Randomized Study.

Transplantation of Cord Blood Expanded Ex Vivo with Copper Chelator.

CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only